Watson Farley & Williams (“WFW”) advised minority shareholders in Italian cell technology company Rigenerand on its sale to Evotec.
Founded as a spin-off of the University of Modena and Reggio Emilia in 2009, Rigenerand is a pioneering company in the field of advanced stem cell-based cancer therapies while Evotec is a leading life science company headquartered in Hamburg.
The WFW Italy Corporate team was led by Partner Carlo Cosmelli, supported by Senior Associate Roberta Sturiale.
